Current therapeutic targets for the treatment of Alzheimer’s disease

References

• Rogers SL, Doody RS, Mohs RC, Friedhoff LT. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch. Intern. Med.158(9), 1021–1031 (1998).
   PubMed Web of Science ®Google Scholar
• Rogers SL, Doody RS, Pratt RD, Ieni JR. Long-term efficacy and safety of donepezil in the treatment of Alzheimer’s disease: final analysis of a US multicentre open-label study. Eur. Neuropsychopharmacol.10(3), 195–203 (2000).
   PubMed Web of Science ®Google Scholar
• Tariot PN, Cummings JL, Katz IR et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer’s disease in the nursing home setting. J. Am. Geriatr. Soc.49(12), 1590–1599 (2001).
   PubMed Web of Science ®Google Scholar
• Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology54(12), 2269–2276 (2000).
   PubMed Web of Science ®Google Scholar
• Rosler M, Anand R, Cicin-Sain A et al. Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomised controlled trial. Br. Med. J.318(7184), 633–638 (1999).
   PubMed Web of Science ®Google Scholar
• Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology54(12), 2261–2268 (2000).
   PubMed Web of Science ®Google Scholar
• Farlow M, Anand R, Messina J Jr, Hartman R, Veach J. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer’s disease. Eur. Neurol.44(4), 236–241 (2000).
   PubMed Web of Science ®Google Scholar
• Winblad B, Kilander L, Eriksson S et al. Donepezil in patients with severe Alzheimer’s disease: double-blind, parallel-group, placebo-controlled study. Lancet367(9516), 1057–1065 (2006).
   PubMed Web of Science ®Google Scholar
• Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA291(3), 317–324 (2004).
   PubMed Web of Science ®Google Scholar
• van Dyck CH, Tariot PN, Meyers B, Malca Resnick E. A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease. Alzheimer Dis. Assoc. Disord.21(2), 136–143 (2007).
   PubMed Web of Science ®Google Scholar
• Lopez OL, Becker JT, Wahed AS et al. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J. Neurol. Neurosurg. Psychiatry80(6), 600–607 (2009).
   PubMed Web of Science ®Google Scholar
• Atri A, Shaughnessy LW, Locascio JJ, Growdon JH. Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis. Assoc. Disord.22(3), 209–221 (2008).
   PubMed Web of Science ®Google Scholar
• Nordberg A, Winblad B. Reduced number of [3H] nicotine and [3H] acetylcholine binding sites in the frontal cortex of Alzheimer brains. Neurosci. Lett.72(1), 115–119 (1986).
   PubMed Web of Science ®Google Scholar
• Sabbagh MN, Shah F, Reid RT et al. Pathologic and nicotinic receptor binding differences between mild cognitive impairment, Alzheimer disease, and normal aging. Arch. Neurol.63(12), 1771–1776 (2006).
   PubMedGoogle Scholar
• Kadir A, Almkvist O, Wall A, Langstrom B, Nordberg A. PET imaging of cortical 11C-nicotine binding correlates with the cognitive function of attention in Alzheimer’s disease. Psychopharmacology (Berl.)188(4), 509–520 (2006).
   PubMed Web of Science ®Google Scholar
• Mazurov A, Hauser T, Miller CH. Selective α7 nicotinic acetylcholine receptor ligands. Curr. Med. Chem.13(13), 1567–1584 (2006).
   PubMed Web of Science ®Google Scholar
• Haydar SN, Ghiron C, Bettinetti L et al. SAR and biological evaluation of SEN12333/WAY-317538: novel α 7 nicotinic acetylcholine receptor agonist. Bioorg. Med. Chem.17(14), 5247–5258 (2009).
   PubMed Web of Science ®Google Scholar
• Dunbar GC, Kuchibhatla R. Cognitive enhancement in man with ispronicline, a nicotinic partial agonist. J. Mol. Neurosci.30(1–2), 169–172 (2006).
   PubMed Web of Science ®Google Scholar
• Potter A, Corwin J, Lang J, Piasecki M, Lenox R, Newhouse PA. Acute effects of the selective cholinergic channel activator (nicotinic agonist) ABT-418 in Alzheimer’s disease. Psychopharmacology (Berl.)142(4), 334–342 (1999).
   PubMed Web of Science ®Google Scholar
• Marighetto A, Valerio S, Desmedt A, Philippin JN, Trocme-Thibierge C, Morain P. Comparative effects of the a7 nicotinic partial agonist, S 24795, and the cholinesterase inhibitor, donepezil, against aging-related deficits in declarative and working memory in mice. Psychopharmacology (Berl.)197(3), 499–508 (2008).
   PubMed Web of Science ®Google Scholar
• Rissman RA, De Blas AL, Armstrong DM. GABA(A) receptors in aging and Alzheimer’s disease. J. Neurochem.103(4), 1285–1292 (2007).
   PubMed Web of Science ®Google Scholar
• Rossor MN, Garrett NJ, Johnson AL, Mountjoy CQ, Roth M, Iversen LL. A post-mortem study of the cholinergic and GABA systems in senile dementia. Brain105(Pt 2), 313–330 (1982).
   PubMed Web of Science ®Google Scholar
• Mountjoy CQ, Rossor MN, Iversen LL, Roth M. Correlation of cortical cholinergic and GABA deficits with quantitative neuropathological findings in senile dementia. Brain107(Pt 2), 507–518 (1984).
   PubMed Web of Science ®Google Scholar
• Lowe SL, Francis PT, Procter AW, Palmer AM, Davison AN, Bowen DM. γ-aminobutyric acid concentration in brain tissue at two stages of Alzheimer’s disease. Brain111(Pt 4), 785–799 (1988).
   PubMed Web of Science ®Google Scholar
• Ellison DW, Beal MF, Mazurek MF, Bird ED, Martin JB. A postmortem study of amino acid neurotransmitters in Alzheimer’s disease. Ann. Neurol.20(5), 616–621 (1986).
   PubMed Web of Science ®Google Scholar
• Chu DC, Penney JB Jr, Young AB. Cortical GABAB and GABAA receptors in Alzheimer’s disease: a quantitative autoradiographic study. Neurology37(9), 1454–1459 (1987).
   PubMed Web of Science ®Google Scholar
• Froestl W, Gallagher M, Jenkins H et al. SGS742: the first GABA(B) receptor antagonist in clinical trials. Biochem. Pharmacol.68(8), 1479–1487 (2004).
   PubMed Web of Science ®Google Scholar
• Sabbagh MN. Drug development for Alzheimer’s disease: where are we now and where are we headed? Am. J. Geriatr. Pharmacother.7(3), 167–185 (2009).
   PubMed Web of Science ®Google Scholar
• Sternfeld F, Carling RW, Jelley RA et al. Selective, orally active γ-aminobutyric acidA α5 receptor inverse agonists as cognition enhancers. J. Med. Chem.47(9), 2176–2179 (2004).
   PubMed Web of Science ®Google Scholar
• Aisen PS, Saumier D, Briand R et al. A Phase II study targeting amyloid-β with 3APS in mild-to-moderate Alzheimer disease. Neurology67(10), 1757–1763 (2006).
   PubMed Web of Science ®Google Scholar
• King MV, Marsden CA, Fone KC. A role for the 5-HT1A, 5-HT4 and 5-HT6 receptors in learning and memory. Trends Pharmacol. Sci.12(9), 482–492 (2008).
   Web of Science ®Google Scholar
• Kepe V, Barrio JR, Huang SC et al. Serotonin 1A receptors in the living brain of Alzheimer’s disease patients. Proc. Natl Acad. Sci. USA103(3), 702–707 (2006).
   PubMed Web of Science ®Google Scholar
• Truchot L, Costes SN, Zimmer L et al. Up-regulation of hippocampal serotonin metabolism in mild cognitive impairment. Neurology69(10), 1012–1017 (2007).
   PubMed Web of Science ®Google Scholar
• Reynolds GP, Mason SL, Meldrum A et al. 5-hydroxytryptamine (5-HT)4 receptors in post mortem human brain tissue: distribution, pharmacology and effects of neurodegenerative diseases. Br. J. Pharmacol.114(5), 993–998 (1995).
   PubMed Web of Science ®Google Scholar
• Lorke DE, Lu G, Cho E, Yew DT. Serotonin 5-HT2A and 5-HT6 receptors in the prefrontal cortex of Alzheimer and normal aging patients. BMC Neurosci.7, 36 (2006).
   PubMed Web of Science ®Google Scholar
• Lai MK, Tsang SW, Alder JT et al. Loss of serotonin 5-HT2A receptors in the postmortem temporal cortex correlates with rate of cognitive decline in Alzheimer’s disease. Psychopharmacology (Berl.)179(3), 673–677 (2005).
   PubMed Web of Science ®Google Scholar
• Verdurand M, Berod A, Le Bars D, Zimmer L. Effects of amyloid-β peptides on the serotoninergic 5-HT1A receptors in the rat hippocampus. Neurobiol. Aging DOI: 10.1016/j.neurobiolaging. 2009.01.008 (2009) (Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Hasselbalch SG, Madsen K, Svarer C et al. Reduced 5-HT2A receptor binding in patients with mild cognitive impairment. Neurobiol. Aging29(12), 1830–1838 (2008).
   PubMed Web of Science ®Google Scholar
• Elliott MS, Ballard CG, Kalaria RN, Perry R, Hortobagyi T, Francis PT. Increased binding to 5-HT1A and 5-HT2A receptors is associated with large vessel infarction and relative preservation of cognition. Brain132(Pt 7), 1858–1865 (2009).
   PubMed Web of Science ®Google Scholar
• Carli M, Balducci C, Samanin R. Stimulation of 5-HT1A receptors in the dorsal raphe ameliorates the impairment of spatial learning caused by intrahippocampal 7-chloro-kynurenic acid in naive and pretrained rats. Psychopharmacology (Berl.)158(1), 39–47 (2001).
   PubMed Web of Science ®Google Scholar
• Fontana DJ, Daniels SE, Wong EH, Clark RD, Eglen RM. The effects of novel, selective 5-hydroxytryptamine (5-HT)4 receptor ligands in rat spatial navigation. Neuropharmacology36(4–5), 689–696 (1997).
   PubMed Web of Science ®Google Scholar
• Harder JA, Maclean CJ, Alder JT, Francis PT, Ridley RM. The 5-HT1A antagonist, WAY 100635, ameliorates the cognitive impairment induced by fornix transection in the marmoset. Psychopharmacology (Berl.)127(3), 245–254 (1996).
   PubMed Web of Science ®Google Scholar
• Schechter LE, Smith DL, Rosenzweig-Lipson S et al. Lecozotan (SRA-333): a selective serotonin 1A receptor antagonist that enhances the stimulated release of glutamate and acetylcholine in the hippocampus and possesses cognitive-enhancing properties. J. Pharmacol. Exp. Ther.314(3), 1274–1289 (2005).
   PubMed Web of Science ®Google Scholar
• Foley AG, Murphy KJ, Hirst WD et al. The 5-HT6 receptor antagonist SB-271046 reverses scopolamine-disrupted consolidation of a passive avoidance task and ameliorates spatial task deficits in aged rats. Neuropsychopharmacology29(1), 93–100 (2004).
   PubMed Web of Science ®Google Scholar
• Da Silva Costa V, Duchatelle P, Boulouard M, Dauphin F. Selective 5-HT6 receptor blockade improves spatial recognition memory and reverses age-related deficits in spatial recognition memory in the mouse. Neuropsychopharmacology34(2), 488–500 (2009).
   PubMed Web of Science ®Google Scholar
• Patat A, Parks V, Raje S, Plotka A, Chassard D, Le Coz F. Safety, tolerability, pharmacokinetics and pharmacodynamics of ascending single and multiple doses of lecozotan in healthy young and elderly subjects. Br. J. Clin. Pharmacol.67(3), 299–308 (2009).
   PubMed Web of Science ®Google Scholar
• Upton N, Chuang TT, Hunter AJ, Virley DJ. 5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer’s disease. Neurotherapeutics5(3), 458–469 (2008).
   PubMed Web of Science ®Google Scholar
• Lovenberg TW, Roland BL, Wilson SJ et al. Cloning and functional expression of the human histamine H3 receptor. Mol. Pharmacol.55(6), 1101–1107 (1999).
   PubMed Web of Science ®Google Scholar
• Esbenshade TA, Browman KE, Bitner RS, Strakhova M, Cowart MD, Brioni JD. The histamine H3 receptor: an attractive target for the treatment of cognitive disorders. Br. J. Pharmacol.154(6), 1166–1181 (2008).
   PubMed Web of Science ®Google Scholar
• Medhurst AD, Roberts JC, Lee J et al. Characterization of histamine H3 receptors in Alzheimer’s disease brain and amyloid over-expressing TASTPM mice. Br. J. Pharmacol.157(1), 130–138 (2009).
   PubMed Web of Science ®Google Scholar
• Leurs R, Bakker RA, Timmerman H, de Esch IJ. The histamine H3 receptor: from gene cloning to H3 receptor drugs. Nat. Rev. Drug Discov.4(2), 107–120 (2005).
   PubMed Web of Science ®Google Scholar
• Tully T, Bourtchouladze R, Scott R, Tallman J. Targeting the CREB pathway for memory enhancers. Nat. Rev. Drug Discov.2(4), 267–277 (2003).
   PubMed Web of Science ®Google Scholar
• Barco A, Pittenger C, Kandel ER. CREB, memory enhancement and the treatment of memory disorders: promises, pitfalls and prospects. Expert Opin. Ther. Targets7(1), 101–114 (2003).
   PubMed Web of Science ®Google Scholar
• Vitolo OV, Sant’ Angelo A, Costanzo V, Battaglia F, Arancio O, Shelanski M. Amyloid β-peptide inhibition of the PKA/CREB pathway and long-term potentiation: reversibility by drugs that enhance cAMP signaling. Proc. Natl Acad. Sci. USA99(20), 13217–13221 (2002).
   PubMed Web of Science ®Google Scholar
• Dall’Igna OP, Fett P, Gomes MW, Souza DO, Cunha RA, Lara DR. Caffeine and adenosine A2a receptor antagonists prevent β-amyloid (25–35)-induced cognitive deficits in mice. Exp. Neurol.203(1), 241–245 (2007).
   PubMed Web of Science ®Google Scholar
• Gong B, Vitolo OV, Trinchese F, Liu S, Shelanski M, Arancio O. Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment. J. Clin. Invest.114(11), 1624–1634 (2004).
   PubMed Web of Science ®Google Scholar
• Puzzo D, Staniszewski A, Deng SX et al. Phosphodiesterase 5 inhibition improves synaptic function, memory, and amyloid-β load in an Alzheimer’s disease mouse model. J. Neurosci.29(25), 8075–8086 (2009).
   PubMed Web of Science ®Google Scholar
• Xia M, Huang R, Guo V et al. Identification of compounds that potentiate CREB signaling as possible enhancers of long-term memory. Proc. Natl Acad. Sci. USA106(7), 2412–2417 (2009).
   PubMed Web of Science ®Google Scholar
• Schultheiss D, Muller SV, Nager W et al. Central effects of sildenafil (Viagra) on auditory selective attention and verbal recognition memory in humans: a study with event-related brain potentials. World J. Urol.19(1), 46–50 (2001).
   PubMed Web of Science ®Google Scholar
• Langbaum JB, Chen K, Lee W et al. Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer’s Disease Neuroimaging Initiative (ADNI). Neuroimage45(4), 1107–1116 (2009).
   PubMed Web of Science ®Google Scholar
• Reiman EM, Caselli RJ, Yun LS et al. Preclinical evidence of Alzheimer’s disease in persons homozygous for the e4 allele for apolipoprotein E. N. Engl. J. Med.334(12), 752–758 (1996).
   PubMed Web of Science ®Google Scholar
• Manning CA, Stone WS, Korol DL, Gold PE. Glucose enhancement of 24-h memory retrieval in healthy elderly humans. Behav. Brain Res.93(1–2), 71–76 (1998).
   PubMed Web of Science ®Google Scholar
• Craft S, Asthana S, Newcomer JW et al. Enhancement of memory in Alzheimer disease with insulin and somatostatin, but not glucose. Arch. Gen. Psychiatry56(12), 1135–1140 (1999).
   PubMed Web of Science ®Google Scholar
• Costantini LC, Barr LJ, Vogel JL, Henderson ST. Hypometabolism as a therapeutic target in Alzheimer’s disease. BMC Neurosci.9(Suppl. 2), S16 (2008).
   Web of Science ®Google Scholar
• Henderson ST, Vogel JL, Barr LJ, Garvin F, Jones JJ, Costantini LC. Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer’s disease: a randomized, double-blind, placebo-controlled, multicenter trial. Nutr. Metab. (Lond.)6, 31 (2009).
   PubMed Web of Science ®Google Scholar
• Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch. Neurol.61(5), 661–666 (2004).
   PubMed Web of Science ®Google Scholar
• Qiu WQ, Walsh DM, Ye Z et al. Insulin-degrading enzyme regulates extracellular levels of amyloid β-protein by degradation. J. Biol. Chem.273(49), 32730–32738 (1998).
   PubMed Web of Science ®Google Scholar
• Vekrellis K, Ye Z, Qiu WQ et al. Neurons regulate extracellular levels of amyloid β-protein via proteolysis by insulin-degrading enzyme. J. Neurosci.20(5), 1657–1665 (2000).
   PubMed Web of Science ®Google Scholar
• Risner ME, Saunders AM, Altman JF et al. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer’s disease. Pharmacogenomics J.6(4), 246–254 (2006).
   PubMed Web of Science ®Google Scholar
• Gold M, Alderton C, Zvartau-Hind M et al. Effects of rosiglitazone as a monotherapy in apoe4-stratified subjects with mild-to-moderate Alzheimer’s disease. Alzheimer’s Dement.5(4), P86 (2009) (Poster O1-04-06).
   Google Scholar
• Reger MA, Watson GS, Green PS et al. Intranasal insulin improves cognition and modulates β-amyloid in early AD. Neurology70(6), 440–448 (2008).
   PubMed Web of Science ®Google Scholar
• Selkoe DJ. The molecular pathology of Alzheimer’s disease. Neuron6(4), 487–498 (1991).
   PubMed Web of Science ®Google Scholar
• Hardy J. The amyloid hypothesis for Alzheimer’s disease: a critical reappraisal. J. Neurochem.110(4), 1129–1134 (2009).
   PubMed Web of Science ®Google Scholar
• Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science297(5580), 353–356 (2002).
   PubMed Web of Science ®Google Scholar
• Hardy JA, Higgins GA. Alzheimer’s disease: the amyloid cascade hypothesis. Science256(5054), 184–185 (1992).
   PubMed Web of Science ®Google Scholar
• Glenner GG, Wong CW. Alzheimer’s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun.120(3), 885–890 (1984).
   PubMed Web of Science ®Google Scholar
• Thinakaran G, Koo EH. Amyloid precursor protein trafficking, processing, and function. J. Biol. Chem.283(44), 29615–29619 (2008).
   PubMed Web of Science ®Google Scholar
• LaFerla FM, Green KN, Oddo S. Intracellular amyloid-β in Alzheimer’s disease. Nat. Rev. Neurosci.8(7), 499–509 (2007).
   PubMed Web of Science ®Google Scholar
• Shankar GM, Li S, Mehta TH et al. Amyloid-β protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory. Nat. Med.14(8), 837–842 (2008).
   PubMed Web of Science ®Google Scholar
• Ringman JM. What the study of persons at risk for familial Alzheimer’s disease can tell us about the earliest stages of the disorder: a review. J. Geriatr. Psychiatry Neurol.18(4), 228–233 (2005).
   PubMed Web of Science ®Google Scholar
• Rogaeva E, Kawarai T, George-Hyslop PS. Genetic complexity of Alzheimer’s disease: successes and challenges. J. Alzheimers Dis.9(3 Suppl.), 381–387 (2006).
   PubMed Web of Science ®Google Scholar
• Blennow K, de Leon MJ, Zetterberg H. Alzheimer’s disease. Lancet368(9533), 387–403 (2006).
   PubMed Web of Science ®Google Scholar
• Levey AI, Kitt CA, Simonds WF, Price DL, Brann MR. Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies. J. Neurosci.11(10), 3218–3226 (1991).
   PubMed Web of Science ®Google Scholar
• Anagnostaras SG, Murphy GG, Hamilton SE et al. Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice. Nat. Neurosci.6(1), 51–58 (2003).
   PubMed Web of Science ®Google Scholar
• Fisher A, Pittel Z, Haring R et al. M1 muscarinic agonists can modulate some of the hallmarks in Alzheimer’s disease: implications in future therapy. J. Mol. Neurosci.20(3), 349–356 (2003).
   PubMed Web of Science ®Google Scholar
• Caccamo A, Oddo S, Billings LM et al. M1 receptors play a central role in modulating AD-like pathology in transgenic mice. Neuron49(5), 671–682 (2006).
   PubMed Web of Science ®Google Scholar
• Langmead CJ, Watson J, Reavill C. Muscarinic acetylcholine receptors as CNS drug targets. Pharmacol. Ther.117(2), 232–243 (2008).
   PubMed Web of Science ®Google Scholar
• Nitsch RM, Deng M, Tennis M, Schoenfeld D, Growdon JH. The selective muscarinic M1 agonist AF102B decreases levels of total Aβ in cerebrospinal fluid of patients with Alzheimer’s disease. Ann. Neurol.48(6), 913–918 (2000).
   PubMed Web of Science ®Google Scholar
• Holsinger RM, McLean CA, Beyreuther K, Masters CL, Evin G. Increased expression of the amyloid precursor β-secretase in Alzheimer’s disease. Ann. Neurol.51(6), 783–786 (2002).
   PubMed Web of Science ®Google Scholar
• Yang LB, Lindholm K, Yan R et al. Elevated β-secretase expression and enzymatic activity detected in sporadic Alzheimer disease. Nat. Med.9(1), 3–4 (2003).
   PubMed Web of Science ®Google Scholar
• Fukumoto H, Cheung BS, Hyman BT, Irizarry MC. β-secretase protein and activity are increased in the neocortex in Alzheimer disease. Arch. Neurol.59(9), 1381–1389 (2002).
   PubMed Web of Science ®Google Scholar
• Luo Y, Bolon B, Kahn S et al. Mice deficient in BACE1, the Alzheimer’s β-secretase, have normal phenotype and abolished β-amyloid generation. Nat. Neurosci.4(3), 231–232 (2001).
   PubMed Web of Science ®Google Scholar
• Roberds SL, Anderson J, Basi G et al. BACE knockout mice are healthy despite lacking the primary β-secretase activity in brain: implications for Alzheimer’s disease therapeutics. Hum. Mol. Genet.10(12), 1317–1324 (2001).
   PubMed Web of Science ®Google Scholar
• Ghosh AK, Kumaragurubaran N, Hong L et al. Design, synthesis, and x-ray structure of potent memapsin 2 (β-secretase) inhibitors with isophthalamide derivatives as the P2-P3-ligands. J. Med. Chem.50(10), 2399–2407 (2007).
   PubMed Web of Science ®Google Scholar
• Ghosh AK, Gemma S, Tang J. β-secretase as a therapeutic target for Alzheimer’s disease. Neurotherapeutics5(3), 399–408 (2008).
   PubMed Web of Science ®Google Scholar
• Wolfe MS. Inhibition and modulation of γ-secretase for Alzheimer’s disease. Neurotherapeutics5(3), 391–398 (2008).
   PubMed Web of Science ®Google Scholar
• Wong PC, Zheng H, Chen H et al. Presenilin 1 is required for Notch1 and DII1 expression in the paraxial mesoderm. Nature387(6630), 288–292 (1997).
   PubMed Web of Science ®Google Scholar
• Louvi A, Artavanis-Tsakonas S. Notch signalling in vertebrate neural development. Nat. Rev. Neurosci.7(2), 93–102 (2006).
   PubMed Web of Science ®Google Scholar
• Lai EC. Notch signaling: control of cell communication and cell fate. Development131(5), 965–973 (2004).
   PubMed Web of Science ®Google Scholar
• Lathia JD, Mattson MP, Cheng A. Notch: from neural development to neurological disorders. J. Neurochem.107(6), 1471–1481 (2008).
   PubMed Web of Science ®Google Scholar
• Golde TE, Kukar TL. Medicine. Avoiding unintended toxicity. Science324(5927), 603–604 (2009).
   PubMed Web of Science ®Google Scholar
• Siemers ER, Dean RA, Friedrich S et al. Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-β after inhibition of γ-secretase. Clin. Neuropharmacol.30(6), 317–325 (2007).
   PubMed Web of Science ®Google Scholar
• Siemers ER, Quinn JF, Kaye J et al. Effects of a γ-secretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology66(4), 602–604 (2006).
   PubMed Web of Science ®Google Scholar
• Imbimbo BP. Therapeutic potential of γ-secretase inhibitors and modulators. Curr. Top. Med. Chem.8(1), 54–61 (2008).
   PubMed Web of Science ®Google Scholar
• Fleisher AS, Raman R, Siemers ER et al. Phase 2 safety trial targeting amyloid β production with a γ-secretase inhibitor in Alzheimer disease. Arch. Neurol.65(8), 1031–1038 (2008).
   PubMed Web of Science ®Google Scholar
• Bateman RJ, Siemers ER, Mawuenyega KG et al. A γ-secretase inhibitor decreases amyloid-β production in the central nervous system. Ann. Neurol.66(1), 48–54 (2009).
   PubMed Web of Science ®Google Scholar
• Albright C, Dockens R, Olson R et al. BMS-708163, a potent and selective γ-secretase inhibitor, decreases CSF Aβ at safe and tolerable doses in animals and humans. Program and Abstracts of the International Conference on Alzheimer’s Disease. Chicago, IL, USA, 26–31 July 2008 (Abstract HT-01-05).
   Google Scholar
• Weggen S, Eriksen JL, Das P et al. A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity. Nature414(6860), 212–216 (2001).
   PubMed Web of Science ®Google Scholar
• Weggen S, Eriksen JL, Sagi SA et al. Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid β 42 production by direct modulation of γ-secretase activity. J. Biol. Chem.278(34), 31831–31837 (2003).
   PubMed Web of Science ®Google Scholar
• Hendrix SB, Wilcock GK. What we have learned from the Myriad trials. J. Nutr. Health Aging13(4), 362–364 (2009).
   PubMed Web of Science ®Google Scholar
• Green RC, Schneider LS, Amato DA et al. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA302(23), 2557–2564 (2009).
   PubMed Web of Science ®Google Scholar
• Clarke EE, Churcher I, Ellis S et al. Intra- or intercomplex binding to the γ-secretase enzyme. A model to differentiate inhibitor classes. J. Biol. Chem.281(42), 31279–31289 (2006).
   PubMed Web of Science ®Google Scholar
• Kukar TL, Ladd TB, Bann MA et al. Substrate-targeting γ-secretase modulators. Nature453(7197), 925–929 (2008).
   PubMed Web of Science ®Google Scholar
• Tanzi RE, Moir RD, Wagner SL. Clearance of Alzheimer’s Aβ peptide: the many roads to perdition. Neuron43(5), 605–608 (2004).
   PubMed Web of Science ®Google Scholar
• Turner AJ, Tanzawa K. Mammalian membrane metallopeptidases: NEP, ECE, KELL, and PEX. FASEB J.11(5), 355–364 (1997).
   PubMed Web of Science ®Google Scholar
• Iwata N, Tsubuki S, Takaki Y et al. Identification of the major Aβ1–42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat. Med.6(2), 143–150 (2000).
   PubMed Web of Science ®Google Scholar
• Eckman EA, Adams SK, Troendle FJ et al. Regulation of steady-state β-amyloid levels in the brain by neprilysin and endothelin-converting enzyme but not angiotensin-converting enzyme. J. Biol. Chem.281(41), 30471–30478 (2006).
   PubMed Web of Science ®Google Scholar
• Eckman EA, Reed DK, Eckman CB. Degradation of the Alzheimer’s amyloid β peptide by endothelin-converting enzyme. J. Biol. Chem.276(27), 24540–24548 (2001).
   PubMed Web of Science ®Google Scholar
• Nalivaeva NN, Fisk LR, Belyaev ND, Turner AJ. Amyloid-degrading enzymes as therapeutic targets in Alzheimer’s disease. Curr. Alzheimer Res.5(2), 212–224 (2008).
   PubMed Web of Science ®Google Scholar
• Yasojima K, McGeer EG, McGeer PL. Relationship between β amyloid peptide generating molecules and neprilysin in Alzheimer disease and normal brain. Brain Res.919(1), 115–121 (2001).
   PubMed Web of Science ®Google Scholar
• Farris W, Mansourian S, Chang Y et al. Insulin-degrading enzyme regulates the levels of insulin, amyloid β-protein, and the β-amyloid precursor protein intracellular domain in vivo. Proc. Natl Acad. Sci. USA100(7), 4162–4167 (2003).
   PubMed Web of Science ®Google Scholar
• Meilandt WJ, Cisse M, Ho K et al. Neprilysin overexpression inhibits plaque formation but fails to reduce pathogenic Aβ oligomers and associated cognitive deficits in human amyloid precursor protein transgenic mice. J. Neurosci.29(7), 1977–1986 (2009).
   PubMed Web of Science ®Google Scholar
• Leissring MA, Farris W, Chang AY et al. Enhanced proteolysis of β-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron40(6), 1087–1093 (2003).
   PubMed Web of Science ®Google Scholar
• Poirier R, Wolfer DP, Welzl H et al. Neuronal neprilysin overexpression is associated with attenuation of Aβ-related spatial memory deficit. Neurobiol. Dis.24(3), 475–483 (2006).
   PubMed Web of Science ®Google Scholar
• Iwata N, Mizukami H, Shirotani K et al. Presynaptic localization of neprilysin contributes to efficient clearance of amyloid-β peptide in mouse brain. J. Neurosci.24(4), 991–998 (2004).
   PubMed Web of Science ®Google Scholar
• Marr RA, Rockenstein E, Mukherjee A et al. Neprilysin gene transfer reduces human amyloid pathology in transgenic mice. J. Neurosci.23(6), 1992–1996 (2003).
   PubMed Web of Science ®Google Scholar
• Saito T, Iwata N, Tsubuki S et al. Somatostatin regulates brain amyloid β peptide Aβ42 through modulation of proteolytic degradation. Nat. Med.11(4), 434–439 (2005).
   PubMed Web of Science ®Google Scholar
• Cabrol C, Huzarska MA, Dinolfo C et al. Small-molecule activators of insulin-degrading enzyme discovered through high-throughput compound screening. PLoS One4(4), e5274 (2009).
   PubMed Web of Science ®Google Scholar
• Schenk D, Barbour R, Dunn W et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature400(6740), 173–177 (1999).
   PubMed Web of Science ®Google Scholar
• Morgan D, Diamond DM, Gottschall PE et al. Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer’s disease. Nature408(6815), 982–985 (2000).
   PubMed Web of Science ®Google Scholar
• Wilcock DM, Gharkholonarehe N, Van Nostrand WE, Davis J, Vitek MP, Colton CA. Amyloid reduction by amyloid-β vaccination also reduces mouse tau pathology and protects from neuron loss in two mouse models of Alzheimer’s disease. J. Neurosci.29(25), 7957–7965 (2009).
   PubMed Web of Science ®Google Scholar
• Orgogozo JM, Gilman S, Dartigues JF et al. Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization. Neurology61(1), 46–54 (2003).
   PubMed Web of Science ®Google Scholar
• Hock C, Konietzko U, Streffer JR et al. Antibodies against β-amyloid slow cognitive decline in Alzheimer’s disease. Neuron38(4), 547–554 (2003).
   PubMed Web of Science ®Google Scholar
• Gilman S, Koller M, Black RS et al. Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial. Neurology64(9), 1553–1562 (2005).
   PubMed Web of Science ®Google Scholar
• Vellas B, Black R, Thal LJ et al. Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders. Curr. Alzheimer Res.6(2), 144–151 (2009).
   PubMed Web of Science ®Google Scholar
• Holmes C, Boche D, Wilkinson D et al. Long-term effects of Aβ42 immunisation in Alzheimer’s disease: follow-up of a randomised, placebo-controlled Phase I trial. Lancet372(9634), 216–223 (2008).
   PubMed Web of Science ®Google Scholar
• Masliah E, Hansen L, Adame A et al. Aβ vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology64(1), 129–131 (2005).
   PubMed Web of Science ®Google Scholar
• Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report. Nat. Med.9(4), 448–452 (2003).
   PubMed Web of Science ®Google Scholar
• St George-Hyslop PH, Morris JC. Will anti-amyloid therapies work for Alzheimer’s disease? Lancet372(9634), 180–182 (2008).
   PubMed Web of Science ®Google Scholar
• Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM. Aβ immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron43(3), 321–332 (2004).
   PubMed Web of Science ®Google Scholar
• Hartman RE, Izumi Y, Bales KR, Paul SM, Wozniak DF, Holtzman DM. Treatment with an amyloid-β antibody ameliorates plaque load, learning deficits, and hippocampal long-term potentiation in a mouse model of Alzheimer’s disease. J. Neurosci.25(26), 6213–6220 (2005).
   PubMed Web of Science ®Google Scholar
• Bard F, Cannon C, Barbour R et al. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med.6(8), 916–919 (2000).
   PubMed Web of Science ®Google Scholar
• Koenigsknecht-Talboo J, Meyer-Luehmann M, Parsadanian M et al. Rapid microglial response around amyloid pathology after systemic anti-Aβ antibody administration in PDAPP mice. J. Neurosci.28(52), 14156–14164 (2008).
   PubMed Web of Science ®Google Scholar
• Wilcock DM, DiCarlo G, Henderson D et al. Intracranially administered anti-Aβ antibodies reduce β-amyloid deposition by mechanisms both independent of and associated with microglial activation. J. Neurosci.23(9), 3745–3751 (2003).
   PubMed Web of Science ®Google Scholar
• Wilcock DM, Munireddy SK, Rosenthal A, Ugen KE, Gordon MN, Morgan D. Microglial activation facilitates Aβ plaque removal following intracranial anti-Aβ antibody administration. Neurobiol. Dis.15(1), 11–20 (2004).
   PubMed Web of Science ®Google Scholar
• Takata K, Hirata-Fukae C, Becker AG et al. Deglycosylated anti-amyloid β antibodies reduce microglial phagocytosis and cytokine production while retaining the capacity to induce amyloid β sequestration. Eur. J. Neurosci.26(9), 2458–2468 (2007).
   PubMed Web of Science ®Google Scholar
• Wilcock DM, Rojiani A, Rosenthal A et al. Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J. Neurosci.24(27), 6144–6151 (2004).
   PubMed Web of Science ®Google Scholar
• Das P, Howard V, Loosbrock N, Dickson D, Murphy MP, Golde TE. Amyloid-β immunization effectively reduces amyloid deposition in FcRγ-/- knock-out mice. J. Neurosci.23(24), 8532–8538 (2003).
   PubMed Web of Science ®Google Scholar
• Kellner A, Matschke J, Bernreuther C, Moch H, Ferrer I, Glatzel M. Autoantibodies against β-amyloid are common in Alzheimer’s disease and help control plaque burden. Ann. Neurol.65(1), 24–31 (2009).
   PubMed Web of Science ®Google Scholar
• Relkin NR, Szabo P, Adamiak B et al. 18-month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol. Aging30(11), 1728–1736. (2008).
   PubMed Web of Science ®Google Scholar
• Ladu MJ, Reardon C, Van Eldik L et al. Lipoproteins in the central nervous system. Ann. NY Acad. Sci.903, 167–175 (2000).
   PubMed Web of Science ®Google Scholar
• Corder EH, Saunders AM, Strittmatter WJ et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science261(5123), 921–923 (1993).
   PubMed Web of Science ®Google Scholar
• Schmechel DE, Saunders AM, Strittmatter WJ et al. Increased amyloid β-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc. Natl Acad. Sci. USA90(20), 9649–9653 (1993).
   PubMed Web of Science ®Google Scholar
• Reiman EM, Chen K, Liu X et al. Fibrillar amyloid-β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer’s disease. Proc. Natl Acad. Sci. USA106(16), 6820–6825 (2009).
   PubMed Web of Science ®Google Scholar
• Fan J, Donkin J, Wellington C. Greasing the wheels of Aβ clearance in Alzheimer’s disease: The role of lipids and apolipoprotein E. Biofactors35(3), 239–248 (2009).
   PubMed Web of Science ®Google Scholar
• Martel CL, Mackic JB, Matsubara E et al. Isoform-specific effects of apolipoproteins E2, E3, and E4 on cerebral capillary sequestration and blood–brain barrier transport of circulating Alzheimer’s amyloid β. J. Neurochem.69(5), 1995–2004 (1997).
   PubMed Web of Science ®Google Scholar
• Bales KR, Verina T, Dodel RC et al. Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition. Nat. Genet.17(3), 263–264 (1997).
   PubMed Web of Science ®Google Scholar
• Sadowski MJ, Pankiewicz J, Scholtzova H et al. Blocking the apolipoprotein E/amyloid-β interaction as a potential therapeutic approach for Alzheimer’s disease. Proc. Natl Acad. Sci. USA103(49), 18787–18792 (2006).
   PubMed Web of Science ®Google Scholar
• Zlokovic BV. Clearing amyloid through the blood–brain barrier. J. Neurochem.89(4), 807–811 (2004).
   PubMed Web of Science ®Google Scholar
• Shibata M, Yamada S, Kumar SR et al. Clearance of Alzheimer’s amyloid-ss1–40 peptide from brain by LDL receptor-related protein-1 at the blood–brain barrier. J. Clin. Invest.106(12), 1489–1499 (2000).
   PubMed Web of Science ®Google Scholar
• Deane R, Wu Z, Sagare A et al. LRP/amyloid β-peptide interaction mediates differential brain efflux of Aβ isoforms. Neuron43(3), 333–344 (2004).
   PubMed Web of Science ®Google Scholar
• Sagare A, Deane R, Bell RD et al. Clearance of amyloid-β by circulating lipoprotein receptors. Nat. Med.13(9), 1029–1031 (2007).
   PubMed Web of Science ®Google Scholar
• Brett J, Schmidt AM, Yan SD et al. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am. J. Pathol.143(6), 1699–1712 (1993).
   PubMed Web of Science ®Google Scholar
• Lue LF, Walker DG, Brachova L et al. Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer’s disease: identification of a cellular activation mechanism. Exp. Neurol.171(1), 29–45 (2001).
   PubMed Web of Science ®Google Scholar
• Sasaki N, Toki S, Chowei H et al. Immunohistochemical distribution of the receptor for advanced glycation end products in neurons and astrocytes in Alzheimer’s disease. Brain Res.888(2), 256–262 (2001).
   PubMed Web of Science ®Google Scholar
• Yan SD, Chen X, Fu J et al. RAGE and amyloid-β peptide neurotoxicity in Alzheimer’s disease. Nature382(6593), 685–691 (1996).
   PubMed Web of Science ®Google Scholar
• Deane R, Du Yan S, Submamaryan RK et al. RAGE mediates amyloid-β peptide transport across the blood–brain barrier and accumulation in brain. Nat. Med.9(7), 907–913 (2003).
   PubMed Web of Science ®Google Scholar
• Zlokovic BV, Yamada S, Holtzman D, Ghiso J, Frangione B. Clearance of amyloid β-peptide from brain: transport or metabolism? Nat. Med.6(7), 718 (2000).
   Web of Science ®Google Scholar
• Lesne S, Koh MT, Kotilinek L et al. A specific amyloid-β protein assembly in the brain impairs memory. Nature440(7082), 352–357 (2006).
   PubMed Web of Science ®Google Scholar
• Cheng IH, Scearce-Levie K, Legleiter J et al. Accelerating amyloid-β fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. J. Biol. Chem.282(33), 23818–23828 (2007).
   PubMed Web of Science ®Google Scholar
• Cleary JP, Walsh DM, Hofmeister JJ et al. Natural oligomers of the amyloid-β protein specifically disrupt cognitive function. Nat. Neurosci.8(1), 79–84 (2005).
   PubMed Web of Science ®Google Scholar
• Head E, Pop V, Vasilevko V et al. A two-year study with fibrillar β-amyloid (Aβ) immunization in aged canines: effects on cognitive function and brain Aβ. J. Neurosci.28(14), 3555–3566 (2008).
   PubMed Web of Science ®Google Scholar
• Yan P, Bero AW, Cirrito JR et al. Characterizing the appearance and growth of amyloid plaques in APP/PS1 mice. J. Neurosci.29(34), 10706–10714 (2009).
   PubMed Web of Science ®Google Scholar
• Burdick D, Soreghan B, Kwon M et al. Assembly and aggregation properties of synthetic Alzheimer’s A4/β amyloid peptide analogs. J. Biol. Chem.267(1), 546–554 (1992).
   PubMed Web of Science ®Google Scholar
• Podlisny MB, Ostaszewski BL, Squazzo SL et al. Aggregation of secreted amyloid β-protein into sodium dodecyl sulfate-stable oligomers in cell culture. J. Biol. Chem.270(16), 9564–9570 (1995).
   PubMed Web of Science ®Google Scholar
• Harmeier A, Wozny C, Rost BR et al. Role of amyloid-β glycine 33 in oligomerization, toxicity, and neuronal plasticity. J. Neurosci.29(23), 7582–7590 (2009).
   PubMed Web of Science ®Google Scholar
• Walsh DM, Townsend M, Podlisny MB et al. Certain inhibitors of synthetic amyloid β-peptide (Aβ) fibrillogenesis block oligomerization of natural Aβ and thereby rescue long-term potentiation. J. Neurosci.25(10), 2455–2462 (2005).
   PubMed Web of Science ®Google Scholar
• Necula M, Kayed R, Milton S, Glabe CG. Small molecule inhibitors of aggregation indicate that amyloid β oligomerization and fibrillization pathways are independent and distinct. J. Biol. Chem.282(14), 10311–10324 (2007).
   PubMed Web of Science ®Google Scholar
• Necula M, Breydo L, Milton S et al. Methylene blue inhibits amyloid Aβ oligomerization by promoting fibrillization. Biochemistry46(30), 8850–8860 (2007).
   PubMed Web of Science ®Google Scholar
• McLaurin J, Franklin T, Chakrabartty A, Fraser PE. Phosphatidylinositol and inositol involvement in Alzheimer amyloid-β fibril growth and arrest. J. Mol. Biol.278(1), 183–194 (1998).
   PubMed Web of Science ®Google Scholar
• Townsend M, Cleary JP, Mehta T et al. Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-β oligomers. Ann. Neurol.60(6), 668–676 (2006).
   PubMed Web of Science ®Google Scholar
• McLaurin J, Kierstead ME, Brown ME et al. Cyclohexanehexol inhibitors of Aβ aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat. Med.12(7), 801–808 (2006).
   PubMed Web of Science ®Google Scholar
• Wang J, Ho L, Zhao W et al. Grape-derived polyphenolics prevent Aβ oligomerization and attenuate cognitive deterioration in a mouse model of Alzheimer’s disease. J. Neurosci.28(25), 6388–6392 (2008).
   PubMed Web of Science ®Google Scholar
• Ono K, Condron MM, Ho L et al. Effects of grape seed-derived polyphenols on amyloid β-protein self-assembly and cytotoxicity. J. Biol. Chem.283(47), 32176–32187 (2008).
   PubMed Web of Science ®Google Scholar
• Ma QL, Yang F, Rosario ER et al. β-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin. J. Neurosci.29(28), 9078–9089 (2009).
   PubMed Web of Science ®Google Scholar
• Cole GM, Lim GP, Yang F et al. Prevention of Alzheimer’s disease: omega-3 fatty acid and phenolic anti-oxidant interventions. Neurobiol. Aging26(Suppl. 1), 133–136 (2005).
   PubMed Web of Science ®Google Scholar
• Vingtdeux V, Dreses-Werringloer U, Zhao H, Davies P, Marambaud P. Therapeutic potential of resveratrol in Alzheimer’s disease. BMC Neurosci.9(Suppl. 2), S6 (2008).
   Web of Science ®Google Scholar
• Barberger-Gateau P, Letenneur L, Deschamps V, Peres K, Dartigues JF, Renaud S. Fish, meat, and risk of dementia: cohort study. Br. Med. J.325(7370), 932–933 (2002).
   PubMed Web of Science ®Google Scholar
• Morris MC, Evans DA, Bienias JL et al. Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch. Neurol.60(7), 940–946 (2003).
   PubMed Web of Science ®Google Scholar
• Luchsinger JA, Tang MX, Siddiqui M, Shea S, Mayeux R. Alcohol intake and risk of dementia. J. Am. Geriatr. Soc.52(4), 540–546 (2004).
   PubMed Web of Science ®Google Scholar
• Schaefer EJ, Bongard V, Beiser AS et al. Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham Heart Study. Arch. Neurol.63(11), 1545–1550 (2006).
   PubMed Web of Science ®Google Scholar
• Chandra V, Ganguli M, Pandav R, Johnston J, Belle S, DeKosky ST. Prevalence of Alzheimer’s disease and other dementias in rural India: the Indo–US study. Neurology51(4), 1000–1008 (1998).
   PubMed Web of Science ®Google Scholar
• Chandra V, Pandav R, Dodge HH et al. Incidence of Alzheimer’s disease in a rural community in India: the Indo–US study. Neurology57(6), 985–989 (2001).
   PubMed Web of Science ®Google Scholar
• Lim GP, Calon F, Morihara T et al. A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. J. Neurosci.25(12), 3032–3040 (2005).
   PubMed Web of Science ®Google Scholar
• Green KN, Martinez-Coria H, Khashwji H et al. Dietary docosahexaenoic acid and docosapentaenoic acid ameliorate amyloid-β and tau pathology via a mechanism involving presenilin 1 levels. J. Neurosci.27(16), 4385–4395 (2007).
   PubMed Web of Science ®Google Scholar
• Wang J, Ho L, Zhao Z et al. Moderate consumption of Cabernet Sauvignon attenuates Aβ neuropathology in a mouse model of Alzheimer’s disease. FASEB J.20(13), 2313–2320 (2006).
   PubMed Web of Science ®Google Scholar
• Bush AI, Tanzi RE. Therapeutics for Alzheimer’s disease based on the metal hypothesis. Neurotherapeutics5(3), 421–432 (2008).
   PubMed Web of Science ®Google Scholar
• Bush AI, Pettingell WH Jr, Paradis MD, Tanzi RE. Modulation of Aβ adhesiveness and secretase site cleavage by zinc. J. Biol. Chem.269(16), 12152–12158 (1994).
   PubMed Web of Science ®Google Scholar
• Bush AI, Pettingell WH, Multhaup G et al. Rapid induction of Alzheimer Aβ amyloid formation by zinc. Science265(5177), 1464–1467 (1994).
   PubMed Web of Science ®Google Scholar
• Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, Markesbery WR. Copper, iron and zinc in Alzheimer’s disease senile plaques. J. Neurol. Sci.158(1), 47–52 (1998).
   PubMed Web of Science ®Google Scholar
• Suh SW, Jensen KB, Jensen MS et al. Histochemically-reactive zinc in amyloid plaques, angiopathy, and degenerating neurons of Alzheimer’s diseased brains. Brain Res.852(2), 274–278 (2000).
   PubMed Web of Science ®Google Scholar
• Ibach B, Haen E, Marienhagen J, Hajak G. Clioquinol treatment in familiar early onset of Alzheimer’s disease: a case report. Pharmacopsychiatry38(4), 178–179 (2005).
   PubMed Web of Science ®Google Scholar
• Lannfelt L, Blennow K, Zetterberg H et al. Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer’s disease: a Phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol.7(9), 779–786 (2008).
   PubMed Web of Science ®Google Scholar
• Ritchie CW, Bush AI, Mackinnon A et al. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Aβ amyloid deposition and toxicity in Alzheimer disease: a pilot Phase 2 clinical trial. Arch. Neurol.60(12), 1685–1691 (2003).
   PubMed Web of Science ®Google Scholar
• Cahoon L. The curious case of clioquinol. Nat. Med.15(4), 356–359 (2009).
   PubMed Web of Science ®Google Scholar
• Wang Y, Branicky R, Stepanyan Z et al. The anti-neurodegeneration drug clioquinol inhibits the aging-associated protein CLK-1. J. Biol. Chem.284(1), 314–323 (2009).
   PubMed Web of Science ®Google Scholar
• Bradke F, Dotti CG. Establishment of neuronal polarity: lessons from cultured hippocampal neurons. Curr. Opin. Neurobiol.10(5), 574–581 (2000).
   PubMed Web of Science ®Google Scholar
• Lee VM, Trojanowski JQ. The disordered neuronal cytoskeleton in Alzheimer’s disease. Curr. Opin. Neurobiol.2(5), 653–656 (1992).
   PubMed Web of Science ®Google Scholar
• Clark CM, Xie S, Chittams J et al. Cerebrospinal fluid tau and β-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch. Neurol.60(12), 1696–1702 (2003).
   PubMed Web of Science ®Google Scholar
• Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer’s disease. Neurology42(3 Pt 1), 631–639 (1992).
   PubMed Web of Science ®Google Scholar
• Tariot PN, Aisen PS. Can lithium or valproate untie tangles in Alzheimer’s disease? J. Clin. Psychiatry70(6), 919–921 (2009).
   PubMed Web of Science ®Google Scholar
• Roberson ED, Scearce-Levie K, Palop JJ et al. Reducing endogenous tau ameliorates amyloid β-induced deficits in an Alzheimer’s disease mouse model. Science316(5825), 750–754 (2007).
   PubMed Web of Science ®Google Scholar
• Santacruz K, Lewis J, Spires T et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science309(5733), 476–481 (2005).
   PubMed Web of Science ®Google Scholar
• Makrides V, Shen TE, Bhatia R et al. Microtubule-dependent oligomerization of tau. Implications for physiological tau function and tauopathies. J. Biol. Chem.278(35), 33298–33304 (2003).
   PubMed Web of Science ®Google Scholar
• Crowe A, Huang W, Ballatore C et al. Identification of aminothienopyridazine inhibitors of tau assembly by quantitative high-throughput screening. Biochemistry48(32), 7732–7745 (2009).
   PubMed Web of Science ®Google Scholar
• Wischik C, Staff R. Challenges in the conduct of disease-modifying trials in AD: practical experience from a Phase 2 trial of tau-aggregation inhibitor therapy. J. Nutr. Health Aging13(4), 367–369 (2009).
   PubMed Web of Science ®Google Scholar
• Wischik CM, Edwards PC, Lai RY, Roth M, Harrington CR. Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proc. Natl Acad. Sci. USA93(20), 11213–11218 (1996).
   PubMed Web of Science ®Google Scholar
• Steinhilb ML, Dias-Santagata D, Fulga TA, Felch DL, Feany MB. Tau phosphorylation sites work in concert to promote neurotoxicity in vivo. Mol. Biol. Cell18(12), 5060–5068 (2007).
   PubMed Web of Science ®Google Scholar
• Schneider A, Mandelkow E. Tau-based treatment strategies in neurodegenerative diseases. Neurotherapeutics5(3), 443–457 (2008).
   PubMed Web of Science ®Google Scholar
• Illenberger S, Zheng-Fischhofer Q, Preuss U et al. The endogenous and cell cycle-dependent phosphorylation of tau protein in living cells: implications for Alzheimer’s disease. Mol. Biol. Cell9(6), 1495–1512 (1998).
   PubMed Web of Science ®Google Scholar
• Gong CX, Liu F, Grundke-Iqbal I, Iqbal K. Post-translational modifications of tau protein in Alzheimer’s disease. J. Neural Transm.112(6), 813–838 (2005).
   PubMed Web of Science ®Google Scholar
• Wen Y, Planel E, Herman M et al. Interplay between cyclin-dependent kinase 5 and glycogen synthase kinase 3β mediated by neuregulin signaling leads to differential effects on tau phosphorylation and amyloid precursor protein processing. J. Neurosci.28(10), 2624–2632 (2008).
   PubMed Web of Science ®Google Scholar
• Plattner F, Angelo M, Giese KP. The roles of cyclin-dependent kinase 5 and glycogen synthase kinase 3 in tau hyperphosphorylation. J. Biol. Chem.281(35), 25457–25465 (2006).
   PubMed Web of Science ®Google Scholar
• Leyhe T, Eschweiler GW, Stransky E et al. Increase of BDNF serum concentration in lithium treated patients with early Alzheimer’s disease. J. Alzheimers Dis.16(3), 649–656 (2009).
   PubMed Web of Science ®Google Scholar
• Porsteinsson AP, Tariot PN, Jakimovich LJ et al. Valproate therapy for agitation in dementia: open-label extension of a double-blind trial. Am. J. Geriatr. Psychiatry11(4), 434–440 (2003).
   PubMed Web of Science ®Google Scholar
• Porsteinsson AP, Tariot PN, Erb R, Gaile S. An open trial of valproate for agitation in geriatric neuropsychiatric disorders. Am. J. Geriatr. Psychiatry5(4), 344–351 (1997).
   PubMed Web of Science ®Google Scholar
• Hampel H, Ewers M, Burger K et al. Lithium trial in Alzheimer’s disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. J. Clin. Psychiatry70(6), 922–931 (2009).
   PubMed Web of Science ®Google Scholar
• Tariot PN, Aisen P, Cummings J et al. The ADCS valproate neuroprotection trial: primary efficacy and safety results. Alzheimer’s Dement.5(4) P84–P85 (2009).
   Google Scholar
• Arendash GW, Mori T, Cao C et al. Caffeine reverses cognitive impairment and decreases brain amyloid-β levels in aged Alzheimer’s disease mice. J. Alzheimers Dis.17(3), 661–680 (2009).
   PubMed Web of Science ®Google Scholar
• Maia L, de Mendonca A. Does caffeine intake protect from Alzheimer’s disease? Eur. J. Neurol.9(4), 377–382 (2002).
   PubMed Web of Science ®Google Scholar
• Eskelinen MH, Ngandu T, Tuomilehto J, Soininen H, Kivipelto M. Midlife coffee and tea drinking and the risk of late-life dementia: a population-based CAIDE study. J. Alzheimers Dis.16(1), 85–91 (2009).
   PubMed Web of Science ®Google Scholar
• Arendash GW, Schleif W, Rezai-Zadeh K et al. Caffeine protects Alzheimer’s mice against cognitive impairment and reduces brain β-amyloid production. Neuroscience142(4), 941–952 (2006).
   PubMed Web of Science ®Google Scholar
• Vogelsberg-Ragaglia V, Schuck T, Trojanowski JQ, Lee VM. PP2A mRNA expression is quantitatively decreased in Alzheimer’s disease hippocampus. Exp. Neurol.168(2), 402–412 (2001).
   PubMed Web of Science ®Google Scholar
• Sontag E, Luangpirom A, Hladik C et al. Altered expression levels of the protein phosphatase 2A ABαC enzyme are associated with Alzheimer disease pathology. J. Neuropathol. Exp. Neurol.63(4), 287–301 (2004).
   PubMed Web of Science ®Google Scholar
• Gong CX, Shaikh S, Wang JZ, Zaidi T, Grundke-Iqbal I, Iqbal K. Phosphatase activity toward abnormally phosphorylated tau: decrease in Alzheimer disease brain. J. Neurochem.65(2), 732–738 (1995).
   PubMed Web of Science ®Google Scholar
• Kins S, Crameri A, Evans DR, Hemmings BA, Nitsch RM, Gotz J. Reduced protein phosphatase 2A activity induces hyperphosphorylation and altered compartmentalization of tau in transgenic mice. J. Biol. Chem.276(41), 38193–38200 (2001).
   PubMed Web of Science ®Google Scholar
• Arendt T, Holzer M, Fruth R, Bruckner MK, Gartner U. Paired helical filament-like phosphorylation of tau, deposition of β/A4-amyloid and memory impairment in rat induced by chronic inhibition of phosphatase 1 and 2A. Neuroscience69(3), 691–698 (1995).
   PubMed Web of Science ®Google Scholar
• Iqbal K, Alonso Adel C, El-Akkad E et al. Significance and mechanism of Alzheimer neurofibrillary degeneration and therapeutic targets to inhibit this lesion. J. Mol. Neurosci.19(1–2), 95–99 (2002).
   PubMed Web of Science ®Google Scholar
• Tanimukai H, Kudo T, Tanaka T, Grundke-Iqbal I, Iqbal K, Takeda M. Novel therapeutic strategies for neurodegenerative disease. Psychogeriatrics9(2), 103–109 (2009).
   PubMed Web of Science ®Google Scholar
• Gozes I, Morimoto BH, Tiong J et al. NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP). CNS Drug Rev.11(4), 353–368 (2005).
   PubMedGoogle Scholar
• Divinski I, Mittelman L, Gozes I. A femtomolar acting octapeptide interacts with tubulin and protects astrocytes against zinc intoxication. J. Biol. Chem.279(27), 28531–28538 (2004).
   PubMed Web of Science ®Google Scholar
• Hashimoto Y, Kaneko Y, Tsukamoto E et al. Molecular characterization of neurohybrid cell death induced by Alzheimer’s amyloid-β peptides via p75NTR/PLAIDD. J. Neurochem.90(3), 549–558 (2004).
   PubMed Web of Science ®Google Scholar
• Gozes I, Divinski I. The femtomolar-acting NAP interacts with microtubules: novel aspects of astrocyte protection. J. Alzheimers Dis.6(6 Suppl.), S37–S41 (2004).
   Google Scholar
• Matsuoka Y, Gray AJ, Hirata-Fukae C et al. Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer’s disease at early pathological stage. J. Mol. Neurosci.31(2), 165–170 (2007).
   PubMed Web of Science ®Google Scholar
• Matsuoka Y, Jouroukhin Y, Gray AJ et al. A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer’s disease. J. Pharmacol. Exp. Ther.325(1), 146–153 (2008).
   PubMed Web of Science ®Google Scholar
• Gozes I, Giladi E, Pinhasov A, Bardea A, Brenneman DE. Activity-dependent neurotrophic factor: intranasal administration of femtomolar-acting peptides improve performance in a water maze. J. Pharmacol. Exp. Ther.293(3), 1091–1098 (2000).
   PubMed Web of Science ®Google Scholar
• Oddo S, Vasilevko V, Caccamo A, Kitazawa M, Cribbs DH, LaFerla FM. Reduction of soluble Aβ and tau, but not soluble Aβ alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. J. Biol. Chem.281(51), 39413–39423 (2006).
   PubMed Web of Science ®Google Scholar
• Mendez MF. Frontotemporal dementia: therapeutic interventions. Front. Neurol. Neurosci.24, 168–178 (2009).
   PubMedGoogle Scholar
• Strong MJ, Yang W, Strong WL, Leystra-Lantz C, Jaffe H, Pant HC. Tau protein hyperphosphorylation in sporadic ALS with cognitive impairment. Neurology66(11), 1770–1771 (2006).
   PubMed Web of Science ®Google Scholar
• McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer’s disease: a review of 17 epidemiologic studies. Neurology47(2), 425–432 (1996).
   PubMed Web of Science ®Google Scholar
• Szekely CA, Breitner JC, Fitzpatrick AL et al. NSAID use and dementia risk in the Cardiovascular Health Study: role of APOE and NSAID type. Neurology70(1), 17–24 (2008).
   PubMed Web of Science ®Google Scholar
• Dufouil C, Richard F, Fievet N et al. APOE genotype, cholesterol level, lipid-lowering treatment, and dementia: the Three-City Study. Neurology64(9), 1531–1538 (2005).
   PubMed Web of Science ®Google Scholar
• Haag MD, Hofman A, Koudstaal PJ, Stricker BH, Breteler MM. Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. J. Neurol. Neurosurg. Psychiatry80(1), 13–17 (2009).
   PubMed Web of Science ®Google Scholar
• Sparks DL, Scheff SW, Hunsaker JC 3rd, Liu H, Landers T, Gross DR. Induction of Alzheimer-like β-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp. Neurol.126(1), 88–94 (1994).
   PubMed Web of Science ®Google Scholar
• Aisen PS, Schafer KA, Grundman M et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA289(21), 2819–2826 (2003).
   PubMed Web of Science ®Google Scholar
• Martin BK, Szekely C, Brandt J et al. Cognitive function over time in the Alzheimer’s Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch. Neurol.65(7), 896–905 (2008).
   PubMed Web of Science ®Google Scholar
• Group AR, Lyketsos CG, Breitner JC et al. Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology68(21), 1800–1808 (2007).
   PubMed Web of Science ®Google Scholar
• Meinert CL, Breitner JC. Chronic disease long-term drug prevention trials: lessons from the Alzheimer’s Disease Anti-inflammatory Prevention Trial (ADAPT). Alzheimers Dement.4(1 Suppl. 1), S7–S14 (2008).
   PubMed Web of Science ®Google Scholar
• Arvanitakis Z, Schneider JA, Wilson RS et al. Statins, incident Alzheimer disease, change in cognitive function, and neuropathology. Neurology70(19 Pt 2), 1795–1802 (2008).
   PubMed Web of Science ®Google Scholar
• Rea TD, Breitner JC, Psaty BM et al. Statin use and the risk of incident dementia: the Cardiovascular Health Study. Arch. Neurol.62(7), 1047–1051 (2005).
   PubMed Web of Science ®Google Scholar
• Li G, Larson EB, Sonnen JA et al. Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease. Neurology69(9), 878–885 (2007).
   PubMed Web of Science ®Google Scholar
• Sparks DL, Sabbagh MN, Connor DJ et al. Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch. Neurol.62(5), 753–757 (2005).
   PubMed Web of Science ®Google Scholar
• Jones RW, Kivipelto M, Feldman H et al. The Atorvastatin/Donepezil in Alzheimer’s Disease Study (LEADe): design and baseline characteristics. Alzheimers Dement.4(2), 145–153 (2008).
   PubMed Web of Science ®Google Scholar
• Feldman H, Jones RW, Kivipelto M et al. The LEADe study: a randomized, controlled trial investigating the effect of atorvastatin on cognitive and global function in patients with mild-to-moderate Alzheimer’s disease receiving background therapy of donepezil. Presented at: American Academy of Neurology Meeting. Chicago, IL, USA, 12–19 April 2008 (Abstract LBS.005).
   Google Scholar
• Green DR, Reed JC. Mitochondria and apoptosis. Science281(5381), 1309–1312 (1998).
   PubMed Web of Science ®Google Scholar
• Spierings D, McStay G, Saleh M et al. Connected to death: the (unexpurgated) mitochondrial pathway of apoptosis. Science310(5745), 66–67 (2005).
   PubMed Web of Science ®Google Scholar
• Bachurin SO, Shevtsova EP, Kireeva EG, Oxenkrug GF, Sablin SO. Mitochondria as a target for neurotoxins and neuroprotective agents. Ann. NY Acad. Sci.993, 334–344; discussion 345–339 (2003).
   PubMed Web of Science ®Google Scholar
• Beal MF. Mitochondria take center stage in aging and neurodegeneration. Ann. Neurol.58(4), 495–505 (2005).
   PubMed Web of Science ®Google Scholar
• Caspersen C, Wang N, Yao J et al. Mitochondrial Aβ: a potential focal point for neuronal metabolic dysfunction in Alzheimer’s disease. FASEB J.19(14), 2040–2041 (2005).
   PubMed Web of Science ®Google Scholar
• Sirk D, Zhu Z, Wadia JS et al. Chronic exposure to sub-lethal β-amyloid (Aβ) inhibits the import of nuclear-encoded proteins to mitochondria in differentiated PC12 cells. J. Neurochem.103(5), 1989–2003 (2007).
   PubMed Web of Science ®Google Scholar
• Doody RS, Gavrilova SI, Sano M et al. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer’s disease: a randomised, double-blind, placebo-controlled study. Lancet372(9634), 207–215 (2008).
   PubMed Web of Science ®Google Scholar
• Cummings JL, Doody R, Gavrilova S et al. 18-month data from an open-label extension of a one-year controlled trial of dimebon in mild-to-moderate Alzheimer’s disease. Presented at: The Alzheimer’s Association International Conference on Alzheimer’s Disease. Chicago, IL, USA, 26–31 July 2008 (P4-334).
   Google Scholar
• Urdinguio RG, Sanchez-Mut JV, Esteller M. Epigenetic mechanisms in neurological diseases: genes, syndromes, and therapies. Lancet Neurol.8(11), 1056–1072 (2009).
   PubMed Web of Science ®Google Scholar
• Antonello M, Rotili D, Valente S, Kazantsev AG. Histone deacetylase inhibitors and neurodegenerative disorders: holding the promise. Curr. Pharm. Des.15(34), 3940–3957 (2009).
   PubMed Web of Science ®Google Scholar
• Fischer A, Sananbenesi F, Wang X, Dobbin M, Tsai LH. Recovery of learning and memory is associated with chromatin remodelling. Nature447(7141), 178–182 (2007).
   PubMed Web of Science ®Google Scholar
• Guan JS, Haggarty SJ, Giacometti E et al. HDAC2 negatively regulates memory formation and synaptic plasticity. Nature459(7243), 55–60 (2009).
   PubMed Web of Science ®Google Scholar
• Green KN, Steffan JS, Martinez-Coria H et al. Nicotinamide restores cognition in Alzheimer’s disease transgenic mice via a mechanism involving sirtuin inhibition and selective reduction of Thr231-phosphotau. J. Neurosci.28(45), 11500–11510 (2008).
   PubMed Web of Science ®Google Scholar
• Fumagalli F, Molteni R, Calabrese F, Maj PF, Racagni G, Riva MA. Neurotrophic factors in neurodegenerative disorders: potential for therapy. CNS Drugs22(12), 1005–1019 (2008).
   PubMed Web of Science ®Google Scholar
• Apfel SC. Is the therapeutic application of neurotrophic factors dead? Ann. Neurol.51(1), 8–11 (2002).
   PubMed Web of Science ®Google Scholar
• Blesch A. Neurotrophic factors in neurodegeneration. Brain Pathol.16(4), 295–303 (2006).
   PubMed Web of Science ®Google Scholar
• Eriksdotter Jonhagen M, Nordberg A, Amberla K et al. Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer’s disease. Dement. Geriatr. Cogn. Disord.9(5), 246–257 (1998).
   PubMed Web of Science ®Google Scholar
• Tuszynski MH. Growth-factor gene therapy for neurodegenerative disorders. Lancet Neurol.1(1), 51–57 (2002).
   PubMed Web of Science ®Google Scholar
• Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, Delon MR. Alzheimer’s disease and senile dementia: loss of neurons in the basal forebrain. Science215(4537), 1237–1239 (1982).
   PubMed Web of Science ®Google Scholar
• Tuszynski MH, Thal L, Pay M et al. A Phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat. Med.11(5), 551–555 (2005).
   PubMed Web of Science ®Google Scholar
• Emerich DF, Winn SR, Harper J, Hammang JP, Baetge EE, Kordower JH. Implants of polymer-encapsulated human NGF-secreting cells in the nonhuman primate: rescue and sprouting of degenerating cholinergic basal forebrain neurons. J. Comp. Neurol.349(1), 148–164 (1994).
   PubMed Web of Science ®Google Scholar
• Chen KS, Gage FH. Somatic gene transfer of NGF to the aged brain: behavioral and morphological amelioration. J. Neurosci.15(4), 2819–2825 (1995).
   PubMed Web of Science ®Google Scholar
• Nagahara AH, Bernot T, Moseanko R et al. Long-term reversal of cholinergic neuronal decline in aged non-human primates by lentiviral NGF gene delivery. Exp. Neurol.215(1), 153–159 (2009).
   PubMed Web of Science ®Google Scholar
• Nagahara AH, Merrill DA, Coppola G et al. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer’s disease. Nat. Med.15(3), 331–337 (2009).
   PubMed Web of Science ®Google Scholar
• Bishop KM, Hofer EK, Mehta A et al. Therapeutic potential of CERE-110 (AAV2-NGF): targeted, stable, and sustained NGF delivery and trophic activity on rodent basal forebrain cholinergic neurons. Exp. Neurol.211(2), 574–584 (2008).
   PubMed Web of Science ®Google Scholar
• Alvarez XA, Cacabelos R, Laredo M et al. A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer’s disease. Eur. J. Neurol.13(1), 43–54 (2006).
   PubMed Web of Science ®Google Scholar
• Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer’s disease in the United States and the public health impact of delaying disease onset. Am. J. Public Health88(9), 1337–1342 (1998).
   PubMed Web of Science ®Google Scholar